MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MetaVia (MTVA) completed the last patient visit in the extended 24-week Phase 1 Part 3A study of DA-1726.
Treatment was extended from 16 to 24 weeks, adding eight weeks at 48 mg weekly. The company cited preliminary safety and tolerability observations as the reason. Previously reported Part 3B interim results showed a statistically significant 68.1% placebo-adjusted reduction in liver fat after 16 weeks and 13.5% placebo-adjusted weight loss at Day 109. All five treated participants with liver steatosis at baseline reached liver fat below 5% by Day 109, measured by MRI-PDFF, an MRI-based fat measurement.
MetaVia expects full Parts 3A and 3B data in the first quarter of 2027. It plans a 48-week, non-biopsy Phase 2 study in up to 150 patients with metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), targeting the second half of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointLiver fat fell 68.1% versus placebo after 16 weeks in Part 3B interim results, a statistically significant reduction.
- Moderate pointBody weight fell 13.5% versus placebo at Day 109 in the Part 3B interim analysis.
- Moderate pointHbA1c, a blood-sugar measure, declined significantly in Part 3B interim results.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 2 study planned for up to 150 MetALD/ALD patients over 48 weeks, targeting the second half of 2027.
- Minor pointLast patient visit completed in the extended 24-week Phase 1 Part 3A study of DA-1726.
4 minor points
- Minor pointPreliminary safety and tolerability observations supported extending Part 3A treatment from 16 to 24 weeks at 48 mg weekly.
- Minor pointAll five treated participants with baseline liver steatosis reached MRI-measured liver fat below 5% by Day 109.
- Minor pointVisceral and subcutaneous fat declined, with relatively preserved lean mass in Part 3B interim results.
- Minor point. Forward-looking: it has not happened yet and may not happen.Full Parts 3A and 3B data are expected in the first quarter of 2027.
Negative
- None.
Key Figures
- Part 3A treatment period
- 24 weeks (extended from 16 weeks)
- Phase 1 Part 3A
- Extended dose
- 48 mg weekly for an additional eight weeks
- Phase 1 Part 3A
- Placebo-adjusted liver-fat reduction
- 68.1%
- Phase 1 Part 3B interim results
- Placebo-adjusted weight loss
- 13.5%
- Phase 1 Part 3B interim results
- Full Parts 3A and 3B data
- Expected in the first quarter of 2027
- DA-1726 Phase 1
- Planned Phase 2 study duration
- 48 weeks
- DA-1726 study in MetALD and ALD
- Planned Phase 2 enrollment
- Up to 150 patients
- DA-1726 study in MetALD and ALD
- Planned Phase 2 start
- Targeted for the second half of 2027
- DA-1726 study in MetALD and ALD
Previous Clinical trial Reports
-
Statistically significant uric-acid reduction added to earlier Part 3B interim findings.
-
Part 3B interim results reported liver-fat and weight reductions, alongside a possibly related serious vomiting event.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
dual-receptor agonist medical
mri-pdff medical
hba1c medical
subcutaneous medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks
Positive Part 3B Interim Data Presented at Precision Liver Symposium Demonstrated Statistically Significant
Full Data from Parts 3A and 3B Expected in First Quarter of 2027; Phase 2 Study in MetALD and ALD Planned for Second Half of 2027
"The encouraging preliminary safety and tolerability observations in Part 3A supported our decision to extend treatment for an additional eight weeks at the 48 mg dose, providing an opportunity to further assess the durability of treatment effects and longer-term safety of DA-1726." stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "Simultaneously, we were finalizing the Part 3B interim data for presentation at the Precision Liver Symposium 2026 and advancing preparations for Phase 2 development. The recently reported Part 3B interim results demonstrated a statistically significant
Mr. Kim continued, "We look forward to reporting the full data from Parts 3A and 3B in the first quarter of 2027, which we expect will provide additional insight into the safety, tolerability and metabolic effects of DA-1726. Building on these encouraging findings, we are preparing to initiate a 48-week, non-biopsy Phase 2 study in up to 150 patients with metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), targeted to begin in the second half of 2027."
In the previously reported Phase 1 Part 3B interim analysis, DA-1726 demonstrated a statistically significant
About DA-1726
DA-1726 is a novel GLP1R/GCGR dual agonist being developed to address various cardiometabolic indications, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), which is designed for once weekly, subcutaneous administration. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. It is engineered with a 3:1 GLP1R:GCGR potency ratio intended to balance the complementary effects of GLP1R activation on appetite and glucose control with GCGR activation on energy expenditure and fat breakdown. DA-1726 has a well understood mechanism and preclinical tissue-distribution studies have shown that it concentrates most heavily in adipose tissue and in the liver. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated a
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, engineered with a 3:1 GLP1R:GCGR potency ratio. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated placebo-adjusted reductions of
For more information, please visit www.metaviatx.com.
Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to obtain, maintain, protect and/or enforce sufficient intellectual property rights to execute its commercial strategy; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of preclinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-announces-completion-of-last-patient-visit-in-extended-24-week-phase-1-part-3a-study-of-da-1726-302941712.html
SOURCE MetaVia Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.